A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Internal tandem duplications in fms-like tyrosine kinase 3 (FLT3-ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in FLT3-ITD mutated AML could guide therapy decisions. Existing assays for...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Levis, Mark J., Perl, Alexander E., Altman, Jessica K., Gocke, Christopher D., Bahceci, Erkut, Hill, Jason, Liu, Chaofeng, Xie, Zhiyi, Carson, Andrew R., McClain, Valerie, Stenzel, Timothy T., Miller, Jeffrey E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2018
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916006/
https://ncbi.nlm.nih.gov/pubmed/29643105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018015925
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg